• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis.原发性硬化性胆管炎和细菌性胆管炎患者的例外点缺乏标准化。
Am J Transplant. 2012 Jun;12(6):1603-9. doi: 10.1111/j.1600-6143.2011.03969.x. Epub 2012 Feb 15.
2
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.原发性硬化性胆管炎和细菌性胆管炎患者的等待名单死亡率风险。
Liver Transpl. 2013 Mar;19(3):250-8. doi: 10.1002/lt.23587.
3
Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.原发性硬化性胆管炎患者在终末期肝病模型时代的等待名单存活率。
Liver Transpl. 2011 Nov;17(11):1355-63. doi: 10.1002/lt.22396.
4
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.活体供肝移植可以解决原发性硬化性胆管炎患者在移植机会方面的差异。
Hepatol Commun. 2023 Aug 3;7(8). doi: 10.1097/HC9.0000000000000219. eCollection 2023 Aug 1.
5
Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy.胆汁淤积性肝病患者的候补名单死亡率和移植后生存率 - 分配政策变化的影响。
HPB (Oxford). 2018 Oct;20(10):916-924. doi: 10.1016/j.hpb.2018.03.013. Epub 2018 Jun 21.
6
Center variation in the use of nonstandardized model for end-stage liver disease exception points.中心变异在非标准化模型终末期肝病例外点的使用中。
Liver Transpl. 2013 Dec;19(12):1330-42. doi: 10.1002/lt.23732. Epub 2013 Oct 10.
7
Ethnicity-Specific Differences in Liver Transplant Outcomes Among Adults With Primary Sclerosing Cholangitis: 2005-2017 United Network for Organ Sharing/Organ Procurement and Transplantation Network.2005 - 2017年器官共享联合网络/器官获取与移植网络中,原发性硬化性胆管炎成年患者肝移植结局的种族特异性差异
J Clin Exp Hepatol. 2021 Jan-Feb;11(1):30-36. doi: 10.1016/j.jceh.2020.06.004. Epub 2020 Jun 15.
8
Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.终末期肝病模型例外点在肝转移神经内分泌肿瘤患者中的可变应用及其对患者预后的影响。
Transplantation. 2015 Nov;99(11):2341-6. doi: 10.1097/TP.0000000000000723.
9
Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.原发性硬化性胆管炎患者不同年龄组的表型及肝移植结局差异
Dig Dis Sci. 2017 Nov;62(11):3200-3209. doi: 10.1007/s10620-017-4559-1. Epub 2017 Apr 8.
10
Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era.终末期肝病模型时代原发性硬化性胆管炎肝移植的疗效停滞
Langenbecks Arch Surg. 2014 Dec;399(8):1021-9. doi: 10.1007/s00423-014-1214-6. Epub 2014 Jun 4.

引用本文的文献

1
Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.自身免疫性肝病的临床管理:当前的节点、机遇与挑战
Immunol Res. 2025 Apr 7;73(1):67. doi: 10.1007/s12026-025-09622-9.
2
Liver transplant in primary sclerosing cholangitis: Current trends and future directions.原发性硬化性胆管炎的肝移植:当前趋势与未来方向
World J Hepatol. 2023 Aug 27;15(8):939-953. doi: 10.4254/wjh.v15.i8.939.
3
Exception points for liver transplantation: A Canadian review.肝移植的例外情况:一项加拿大的综述。
Can Liver J. 2023 Jul 26;6(2):201-214. doi: 10.3138/canlivj-2022-0026. eCollection 2023 Jul.
4
The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis-a narrative review article.被忽视的胆汁黏液及其磷脂酰胆碱含量:原发性胆管炎发病机制中的一个潜在因素——一篇叙述性综述文章
Ann Transl Med. 2021 Apr;9(8):738. doi: 10.21037/atm-20-3591.
5
[Surgical treatment of primary sclerosing cholangitis : Experiences from 30 years in a single center cohort with 173 consecutive patients].[原发性硬化性胆管炎的外科治疗:单一中心队列30年173例连续患者的经验]
Chirurg. 2021 Feb;92(2):148-157. doi: 10.1007/s00104-020-01197-5.
6
An Overview on Primary Sclerosing Cholangitis.原发性硬化性胆管炎概述
J Clin Med. 2020 Mar 11;9(3):754. doi: 10.3390/jcm9030754.
7
Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist.胆汁淤积性肝病的预防性护理:给专科医生和亚专科医生的经验之谈
Liver Res. 2019 Jun;3(2):118-127. doi: 10.1016/j.livres.2019.04.001. Epub 2019 May 27.
8
Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management.原发性硬化性胆管炎:诊断与管理简述。
Dig Dis Sci. 2019 Mar;64(3):632-642. doi: 10.1007/s10620-019-05484-y. Epub 2019 Feb 6.
9
Management of bacterial infection in the liver transplant candidate.肝移植候选者细菌感染的管理
World J Hepatol. 2018 Feb 27;10(2):222-230. doi: 10.4254/wjh.v10.i2.222.
10
Liver Transplantation for Cholestatic Liver Diseases in Adults.成人胆汁淤积性肝病的肝移植
Clin Liver Dis. 2016 Feb;20(1):191-203. doi: 10.1016/j.cld.2015.08.011. Epub 2015 Oct 23.

本文引用的文献

1
Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.原发性硬化性胆管炎患者在终末期肝病模型时代的等待名单存活率。
Liver Transpl. 2011 Nov;17(11):1355-63. doi: 10.1002/lt.22396.
2
Liver allocation and distribution: possible next steps.肝脏分配与分配:可能的下一步。
Liver Transpl. 2011 Sep;17(9):1005-12. doi: 10.1002/lt.22349.
3
Liver transplantation in the United States, 1999-2008.美国 1999-2008 年的肝移植情况。
Am J Transplant. 2010 Apr;10(4 Pt 2):1003-19. doi: 10.1111/j.1600-6143.2010.03037.x.
4
Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.终末期肝病模型(MELD)例外准则:MELD例外研究小组及会议(MESSAGE)关于批准那些患有标准MELD公式未考虑疾病而需要肝移植患者的结果与建议。
Liver Transpl. 2006 Dec;12(12 Suppl 3):S128-36. doi: 10.1002/lt.20979.
5
Model for end-stage liver disease (MELD) exception for bacterial cholangitis.细菌性胆管炎的终末期肝病模型(MELD)例外情况。
Liver Transpl. 2006 Dec;12(12 Suppl 3):S91-2. doi: 10.1002/lt.20966.
6
Regional variations in peer reviewed liver allocation under the MELD system.在终末期肝病模型(MELD)系统下同行评审的肝脏分配中的区域差异。
Am J Transplant. 2005 Sep;5(9):2244-7. doi: 10.1111/j.1600-6143.2005.01008.x.
7
New national liver transplant allocation policy: is the regional review board process fair?新的国家肝脏移植分配政策:区域审查委员会程序公平吗?
Liver Transpl. 2004 May;10(5):666-74. doi: 10.1002/lt.20116.

原发性硬化性胆管炎和细菌性胆管炎患者的例外点缺乏标准化。

Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis.

机构信息

Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Am J Transplant. 2012 Jun;12(6):1603-9. doi: 10.1111/j.1600-6143.2011.03969.x. Epub 2012 Feb 15.

DOI:10.1111/j.1600-6143.2011.03969.x
PMID:22335632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3357462/
Abstract

For conditions that the Model for End-Stage Liver Disease (MELD) score does not accurately predict waitlist mortality, transplant centers may apply to regional review boards for exception points. For patients with primary sclerosing cholangitis (PSC) suffering from bacterial cholangitis, consensus recommendations published in December 2006 are to grant exception points for recurrent cholangitis with ≥ 2 episodes of bacteremia or ≥ 1 episode septic complications. Using data provided by the United Network for Organ Sharing, we evaluated PSC patients who applied for exception points due to bacterial cholangitis from February 27, 2002 to March 14, 2011. Before publication of the recommendations, 66.0% of applications were accepted, compared with 80.1% after (p < 0.001). Focusing on applications after publication of the recommendations, 311 (74.6%) did not meet the recommended criteria, and 250 (80.4%) of these were approved. Of patients with approved applications, those not meeting consensus criteria were more likely to be transplanted, (77.4% vs. 62.8%, p = 0.043), whereas those with denied applications for approved indications were more liked to die/be removed (44.4% vs. 9.5%, p = 0.49). Although data are needed to properly identify those patients at highest risk for waitlist mortality, standardized criteria or a centralized review board should be adopted to ensure consistency in the granting of exception points.

摘要

对于模型终末期肝病评分(MELD)不能准确预测等待名单死亡率的情况,移植中心可以向区域审查委员会申请例外积分。对于原发性硬化性胆管炎(PSC)合并细菌性胆管炎的患者,2006 年 12 月发表的共识建议是,对于复发性胆管炎伴有≥2 次菌血症或≥1 次感染性并发症的患者,给予例外积分。利用美国器官共享网络提供的数据,我们评估了由于细菌性胆管炎而在 2002 年 2 月 27 日至 2011 年 3 月 14 日期间申请例外积分的 PSC 患者。在建议发布之前,66.0%的申请被接受,而之后的接受率为 80.1%(p<0.001)。关注建议发布后的申请,有 311 项(74.6%)不符合推荐标准,其中 250 项(80.4%)被批准。在获得批准的申请中,不符合共识标准的患者更有可能接受移植治疗(77.4%比 62.8%,p=0.043),而那些符合批准适应证但申请被拒的患者更有可能死亡/被除名(44.4%比 9.5%,p=0.49)。虽然需要数据来正确识别等待名单死亡率最高的患者,但应采用标准化标准或集中审查委员会,以确保例外积分的授予保持一致。